Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

Title:Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

Volume: 15 Issue: 6

Author(s): Yuechi Sun, Yan He, Yuan Liu and Guixiu Shi

Affiliation:

Keywords: Biologics, dermatomyositis, interstitial lung disease, polymyositis.

Abstract: Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.

Cite this article as:

Sun Yuechi, He Yan, Liu Yuan and Shi Guixiu, Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910145940